Signaling pathways activated by oncogenic forms of Abl tyrosine kinase. - Test2 - elhamkhani - TriplyDB

Signaling pathways activated by oncogenic forms of Abl tyrosine kinase.

Signaling pathways activated by oncogenic forms of Abl tyrosine kinase.

http://www.wikidata.org/entity/Q33663180

about

c-Abl tyrosine kinase binds and phosphorylates phospholipid scramblase 1 Structure of a regulatory complex involving the Abl SH3 domain, the Crk SH2 domain, and a Crk-derived phosphopeptide.Molecular cloning and characterization of TPP36 and its isoform TPP32, novel substrates of Abl tyrosine kinase Mutations affecting the MA portion of the v-Abl protein reveal a conserved role of Gag in Abelson murine leukemia virus (MLV) and Moloney MLV Phosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences.The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.Abelson kinase regulates epithelial morphogenesis in Drosophila.Ral is both necessary and sufficient for the inhibition of myeloid differentiation mediated by Ras Disruption of the Shc/Grb2 complex during abelson virus transformation affects proliferation, but not apoptosis.JAK-STAT signaling activated by Abl oncogenes.p53 deficiency increases transformation by v-Abl and rescues the ability of a C-terminally truncated v-Abl mutant to induce pre-B lymphoma in vivo.Ras in cancer and developmental diseases Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis.NF-kappaB1 can inhibit v-Abl-induced lymphoid transformation by functioning as a negative regulator of cyclin D1 expression.The effect of erythropoietin on normal and neoplastic cells.Epo receptors are not detectable in primary human tumor tissue samples Dissecting the molecular mechanism of chronic myelogenous leukemia using murine models.Post-transcriptional mechanisms in BCR/ABL leukemogenesis: role of shuttling RNA-binding proteins.The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model.Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.Translational regulation by the p210 BCR/ABL oncoprotein.Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.Gag influences transformation by Abelson murine leukemia virus and suppresses nuclear localization of the v-Abl protein Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development Deciphering modular and dynamic behaviors of transcriptional networks Point mutations of protein kinases and individualised cancer therapy.Cancer cell signaling pathways targeted by spice-derived nutraceuticals.Active Akt and functional p53 modulate apoptosis in Abelson virus-transformed pre-B cells.Re-emergence of interferon-α in the treatment of chronic myeloid leukemia In Vitro Apoptotic Effects of Farnesyltransferase blockade in Acute Myeloid Leukemia Cells.Exploring pathways from gene co-expression to network dynamics.Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance.Genomic mechanisms of p210BCR-ABL signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis.BCR-ABL prevents c-jun-mediated and proteasome-dependent FUS (TLS) proteolysis through a protein kinase CbetaII-dependent pathway.Transformation of bone marrow B-cell progenitors by E2a-Hlf requires coexpression of Bcl-2.Abelson virus transformation prevents TRAIL expression by inhibiting FoxO3a and NF-kappaB.Reovirus as a novel oncolytic agent.Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.NF-kappaB/RelA transactivation is required for atypical protein kinase C iota-mediated cell survival.Analysis of protein tyrosine kinase inhibitors in recombinant yeast lacking the ERG6 gene.

P2860

Q24291294-08DF9D76-1C60-47CC-B3CC-476BF5E46940 Q24311589-1406626E-663C-4217-A2A1-A9CAA243EDFF Q28511791-75855CA6-B3F7-4D4B-8957-635DFE824D0B Q28754439-CBF6E046-FEE3-41ED-8909-9A09FCF62A60 Q30160146-3FE4128B-D9B5-4566-917D-068CE52C0085 Q30165112-07A68329-3D6C-421D-A2B2-1D5946CBE917 Q30784507-266D1AF8-F642-4DFC-ABB3-0AFFB3BF660F Q33241589-FD6D8793-24DE-45D9-ADDD-C1D4499E2D7C Q33782337-DA818102-13E9-481C-92A8-6B06D572A5EA Q33941370-E76FDBBA-FD51-43FC-9F02-ED816E6EEFA1 Q33961551-3B14F5DA-1618-4867-B666-8F18C3326EF3 Q34202697-B6412C47-E17A-4F4A-AB23-504F055BD6E8 Q34281241-0430A032-C958-45E6-A323-DEA16D2D5E2F Q34283905-3CF5C6C4-2522-4D57-B2A6-81673EAFAFA7 Q34291437-0EB0781E-D03F-4BF2-91EF-B1F3AEAA15F1 Q34826770-EBC2CDDF-164A-40D4-9797-2A5792C2CF6F Q34980358-D4F2C831-1882-4C11-8FA2-5E598686C28F Q35022522-4C54D9F1-FE28-40E1-9941-D681F8510D20 Q35022540-C30E32EB-D414-4E88-B47F-135F017D582B Q35186888-936A8029-8860-4C93-AB88-C90B15E8AB38 Q35750135-B1DCAF8B-71B9-416C-9559-F9852AF3C59E Q35847734-30DE642A-55AC-4A79-AAD5-AD873940F37B Q35947927-BDC9F367-4CD8-4772-A454-DFFB1D4DFC0D Q35967452-ED1FC779-AD16-4B98-BCE2-53E332AD4BD3 Q36513574-577A34A7-EF62-4E9B-9439-BFDC14DF297F Q36632245-8C5D8401-696C-4B70-95B0-72A5B7E5C971 Q36819371-065BC45D-3038-4F0E-9FC0-77F1E2965F84 Q36961499-ACD732EE-3D3E-44E8-96D9-9EB66D72D233 Q36989407-D6E8DBF4-B367-4F93-9E08-411BF32C670D Q37432558-77A025B3-C823-4340-B732-33A2CB69BE7B Q37450004-E26E70EC-1C57-44C3-81CF-B4ABCB61A2FF Q38132359-D3E2B713-47AA-4DF6-80E6-2CFC272A7134 Q38340918-1CA85266-3ECF-4755-AEB4-CEB0D996DC2A Q39454928-4C4CB168-EA61-4A4C-81B8-1F9A525792ED Q39681536-7BE8DD1D-320B-4D9F-B846-EC891E5C33D2 Q39730593-EC1FEDA0-00E3-43A0-A759-CB69381E3269 Q40365039-0C6AB025-E4D4-4175-80B4-FD6587436013 Q40827710-CD44E07E-AB4A-4BE3-AE30-743B07D7CD21 Q43718779-441A6472-0A38-4939-ADA8-FC9427F968C7 Q44269301-CB27AD99-7DDD-4FED-BC0B-404BF6C9C237

P2860

Signaling pathways activated by oncogenic forms of Abl tyrosine kinase.

http://www.wikidata.org/entity/Q33663180

description

1999 nî lūn-bûn

@nan

1999 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի հունիսին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Signaling pathways activated by oncogenic forms of Abl tyrosine kinase.

@ast

Signaling pathways activated by oncogenic forms of Abl tyrosine kinase.

@en

type

label

Signaling pathways activated by oncogenic forms of Abl tyrosine kinase.

@ast

Signaling pathways activated by oncogenic forms of Abl tyrosine kinase.

@en

prefLabel

Signaling pathways activated by oncogenic forms of Abl tyrosine kinase.

@ast

Signaling pathways activated by oncogenic forms of Abl tyrosine kinase.

@en

P1433

Q33663180-09C75580-AE8C-49A6-B0D7-1870D25676C3

P1476

Q33663180-0779C02C-831F-4A85-9EBF-D40A59B743B4

P2093

Q33663180-4479C6AB-7209-4112-AE64-3009EBA82120

Q33663180-8CDA6EB9-816B-45C6-8882-2AC2D12492EC

P2860

Q33663180-048F1DB0-4854-4688-9366-99ABD9CA6FE1

Q33663180-08657121-CF6C-4CA0-830A-05AC50F52435

Q33663180-0FF8904F-CDF9-4FDC-A6B1-B7AE95C309B5

Q33663180-127E9519-1902-4040-A270-EED57CD180AA

Q33663180-14FF272D-E495-4A7E-A87C-8B0BB0E21DDB

Q33663180-17614975-3CC6-4C39-9C0A-30E8176F8A90

Q33663180-187DFEF8-B0E3-4DFE-84AF-F5B6D057549F

Q33663180-24458BFE-E084-4A94-AC0B-8D7A69537104

Q33663180-293F06AB-7697-4EFC-9835-1DED3AE000B2

Q33663180-2BE06362-E9A4-457B-9069-4E68064431FD

P304

Q33663180-AE20D7C6-71F8-4F43-8C8A-782830073D5B

P31

Q33663180-B5CE8992-2A47-4016-8ABF-7296A596570E

P356

Q33663180-554503DE-4636-4B29-9776-88C1F9FA4DC0

P407

Q33663180-6AEE37B3-B959-4EC3-AF89-F3033E872D2E

P433

Q33663180-B6B437AC-2108-4B93-A0F9-074A7628CC73

P478

Q33663180-183AD9E2-C4BB-4133-B568-F1EC9941CFCF

P577

Q33663180-9A649662-22D5-4A0B-8325-17BAA587EDF5

P698

Q33663180-DE72F909-DF81-414D-8AF7-91C44B54A98D

P356

JBC.274.26.18141

P1433

Journal of Biological Chemistry

P1476

Signaling pathways activated by oncogenic forms of Abl tyrosine kinase.

@en

P2093

Calame K

http://www.w3.org/2001/XMLSchema#string

Zou X

http://www.w3.org/2001/XMLSchema#string

P2860

Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity

p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells

Isolation and characterization of e3B1, an eps8 binding protein that regulates cell growth

The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene

Direct interaction of Jak1 and v-Abl is required for v-Abl-induced activation of STATs and proliferation

Constitutive phosphorylation of eps8 in tumor cell lines: relevance to malignant transformation

Abl protein-tyrosine kinase selects the Crk adapter as a substrate using SH3-binding sites

The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53

Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase

Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation

P304

18141-18144

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.274.26.18141

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

274

http://www.w3.org/2001/XMLSchema#string

P577

1999-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10373409

http://www.w3.org/2001/XMLSchema#string